TEVA—the new CEO, Levin needs more time and I guess he will lower the [guidance] targets.
What, if any, impact do you expect the change of CEO to have on TEVA's existing partnerships? Will TEVA still meaningfully pursue novel cancer targets? In particular, just curious if there's any reason to worry if OGXI's partnership with TEVA for custirsen could be on the chopping block?
Market Data 
Markets 
AI
